Imetelstat Sodium Patent Expiration

Imetelstat Sodium was first introduced by Geron Corp in its drug Rytelo on Jun 6, 2024.


Imetelstat Sodium Patents

Given below is the list of patents protecting Imetelstat Sodium, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Rytelo US12171778 Methods of treating myelodysplastic syndrome Jun 16, 2039 Geron
Rytelo US12442000 Use Of Telomerase Inhibitors For The Treatment Of Myeloproliferative Disorders And Myeloproliferative Neoplasms Mar 15, 2033 Geron
Rytelo US9375485 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms Mar 15, 2033 Geron
Rytelo US7494982 Modified oligonucleotides for telomerase inhibition Dec 27, 2026 Geron
Rytelo US9388415 Modified oligonucleotides for telomerase inhibition Sep 09, 2026

(Expired)

Geron
Rytelo US9388416 Modified oligonucleotides for telomerase inhibition Sep 09, 2026

(Expired)

Geron



Imetelstat Sodium's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Clinical Trials

Recent Clinical Trials on Imetelstat Sodium:

Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis Geron Corporation NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1


Imetelstat Sodium Generic API Manufacturers

Given below is the list of companies who have filed for Imetelstat Sodium generic, along with the locations of their manufacturing plants worldwide.